CytoDyn holds investor call for corporate and clinical update; no material results disclosed in filing

CytoDyn Inc.

Company held investor call on April 30, 2026 at 1:00 p.m. PT to provide corporate and clinical update.
Presentation materials furnished as Exhibit 99.1 titled 'Leronlimab – A Novel Therapeutic in CCR5+ Immuno-Oncology'.
No specific financial or trial data included in the 8-K or exhibit; update is forward-looking without new quantitative details.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.